Samantha Yee

Dr. Samantha Yee

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
LDLin Du
Lin Du
SYSamantha Yee
Samantha Yee
KRKarthik Ramachandran
Karthik Ramachandran
April RisingerApril Risinger
April Risinger
The taccalonolide microtubule stabilizers covalently bind β-tubulin and overcome clinically relevant taxane resistance mechanisms. Evaluations of the target specificity and detailed drug–target interactions of taccalonolides, however, have been limited in part by their irreversible target engagement. In this study, we report the synthesis of fluorogenic taccalonolide probes that maintain the native biological properties of the potent taccalonolide, AJ. These carefully optimized, cell-permeable probes outperform commercial taxane-based probes and enable direct visualization of taccalonolides in both live and fixed cells with dramatic microtubule colocalization. The specificity of taccalonolide binding to β-tubulin is demonstrated by immunoblotting, which allows for determination of the relative contribution of key tubulin residues and taccalonolide moieties for drug–target interactions by activity-based protein profiling utilizing site-directed mutagenesis and computational modeling. This combinatorial approach provides a generally applicable strategy for investigating the binding specificity and molecular interactions of covalent binding drugs in a cellular environment.

1 April 2022 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
HSHan Sun
Han Sun
SYSamantha Yee
Samantha Yee
HGHabtom B. Gobeze
Habtom B. Gobeze
RHRu He
Ru He
DMDaniel Martinez
Daniel Martinez
KSKirk S. Schanze
Kirk S. Schanze

12 December 2020
Verified
Book Chapter
Closed access
PDF file
SYSamantha Yee
Samantha Yee
LDLin Du
Lin Du
April RisingerApril Risinger
April Risinger

20 November 2020 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
NCNicholas A. Clanton
Nicholas A. Clanton
SHShayne D. Hastings
Shayne D. Hastings
GFGriffin B. Foultz
Griffin B. Foultz
JCJulie A. Contreras
Julie A. Contreras
SYSamantha Yee
Samantha Yee
DFDoug E. Frantz
Doug E. Frantz

3 July 2021 in Molecules
Verified
Journal Article
Open access
PDF file
SYSamantha Yee
Samantha Yee
April RisingerApril Risinger
April Risinger
Ovarian cancer often has a poor clinical prognosis because of late detection, frequently after metastatic progression, as well as acquired resistance to taxane-based therapy. Herein, we evaluate a novel class of covalent microtubule stabilizers, the C-22,23-epoxytaccalonolides, for their efficacy against taxane-resistant ovarian cancer models in vitro and in vivo. Taccalonolide AF, which covalently binds β-tubulin through its C-22,23-epoxide moiety, demonstrates efficacy against taxane-resistant models and shows superior persistence in clonogenic assays after drug washout due to irreversible target engagement. In vivo, intraperitoneal administration of taccalonolide AF demonstrated efficacy against the taxane-resistant NCI/ADR-RES ovarian cancer model both as a flank xenograft, as well as in a disseminated orthotopic disease model representing localized metastasis. Taccalonolide-treated animals had a significant decrease in micrometastasis of NCI/ADR-RES cells to the spleen, as detected by quantitative RT-PCR, without any evidence of systemic toxicity. Together, these findings demonstrate that taccalonolide AF retains efficacy in taxane-resistant ovarian cancer models in vitro and in vivo and that its irreversible mechanism of microtubule stabilization has the unique potential for intraperitoneal treatment of locally disseminated taxane-resistant disease, which represents a significant unmet clinical need in the treatment of ovarian cancer patients.

15 April 2026 in Cancers
Verified
Journal Article
Open access
PDF file
NANatalia Antonides-Jensen
Natalia Antonides-Jensen
MSMuskan Singh
Muskan Singh
YXYuqing Xue
Yuqing Xue
FFFernando Flores-Guzman
Fernando Flores-Guzman
LWLydia L Wu
Lydia L Wu
SHSonia L Hernandez
Sonia L Hernandez
Background: High-risk neuroblastoma (NB) is a pediatric malignancy associated with metastases and an immunosuppressive tumor microenvironment. Standard-of-care treatments like chemotherapy are often ineffective, which motivates the investigation of adjuvant approaches. Histotripsy is a noninvasive focused ultrasound therapy that ablates tissue through the mechanical action of bubble clouds. In addition to disruption of the targeted tumor, non-targeted lesions may exhibit growth delay after the histotripsy procedure. The primary hypothesis of this study was histotripsy-induced shifts in the tumor microenvironment will improve the response of metastatic NB to chemotherapy. Methods: Female A/J mice flanks were inoculated bilaterally with 1 × 106 Neuro-2a cells. Histotripsy was applied to one tumor (200–500 mm3), with or without concurrent administration of liposomal doxorubicin (LDOX). The contralateral tumor served as a model of non-targeted distal metastases. Following treatment, tumors were monitored indefinitely for growth, or assessed after 5–7 days with flow cytometry, single-cell RNA sequencing, and immunohistochemistry. Results: Histotripsy alone delayed the growth of treated and contralateral tumors relative to controls (p = 0.01 and p < 0.0001, respectively) and increased CD8+ T and CD11b+ cells (p < 0.05 for both comparisons). Further, NB cells in targeted and contralateral tumors exhibited a decrease in c-Myc expression and cell-cycle activity, and upregulation of interferon and apoptosis pathways. Histotripsy combined with LDOX had the longest delay in tumor growth (p < 0.0001 vs. untreated controls; p < 0.001 vs. other arms) and greatest expression of CD8+ and MOMA staining. Conclusions: These findings indicate that histotripsy induces a systemic antitumor immune response that potentiates chemotherapy efficacy in this model of metastatic NB.